The USPTO issued patent US12594332B2 to Novartis AG on April 7, 2026, covering methods of treating psoriasis using secukinumab, an IL-17 antagonist antibody. The patent contains 11 claims and is classified under CPC codes A61K 39/3955, A61K 2039/505, and A61P 17/06. The invention disclosure describes novel dosing regimens employing secukinumab for therapeutic applications.

Pharmaceutical companies developing biosimilar IL-17 inhibitors or generic psoriasis treatments should assess whether their products or methods fall within the scope of these claims. The patent provides Novartis with exclusivity in the United States for secukinumab treatment methods, which may affect competitive entry strategies and licensing negotiations for other IL-17 targeting therapies.